On October 13, 2025, Excellergy, a biotechnology company developing a new class of allergy therapeutics, announced its launch with a $70 million Series A financing to advance its pipeline of first-in-class allergic Effector Cell Response Inhibitors (ECRIs). Excellergy is backed by leading healthcare investors, with Samsara BioCapital serving as the Series A lead with co-investments from Red Tree Venture Capital and Decheng Capital. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.

The company’s $70 million Series A financing supports advancement into first-in-human studies.

The Wilson Sonsini team that advised Excellergy on the transaction includes:

Corporate
Jennifer Knapp
Sean Mihaljevich
Jake Morales
Maya Prasad

Patents and Innovations
Maya Skubatch
Rex Watkins

For more information, please see Excellergy’s news release. Additional coverage can be found on Fierce Biotech.